MX2023003406A - Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. - Google Patents
Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2.Info
- Publication number
- MX2023003406A MX2023003406A MX2023003406A MX2023003406A MX2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A MX 2023003406 A MX2023003406 A MX 2023003406A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- solid tumors
- tucatinib
- combination
- alterations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084481P | 2020-09-28 | 2020-09-28 | |
| US202063113245P | 2020-11-13 | 2020-11-13 | |
| US202163222335P | 2021-07-15 | 2021-07-15 | |
| PCT/US2021/071606 WO2022067347A1 (en) | 2020-09-28 | 2021-09-27 | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003406A true MX2023003406A (es) | 2023-03-31 |
Family
ID=78464001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003406A MX2023003406A (es) | 2020-09-28 | 2021-09-27 | Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230372342A1 (https=) |
| EP (1) | EP4217400A1 (https=) |
| JP (1) | JP2023543261A (https=) |
| KR (1) | KR20230078705A (https=) |
| CN (1) | CN116437924A (https=) |
| AU (1) | AU2021349384A1 (https=) |
| CA (1) | CA3197165A1 (https=) |
| IL (1) | IL301405A (https=) |
| MX (1) | MX2023003406A (https=) |
| WO (1) | WO2022067347A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230429A1 (en) * | 2022-05-22 | 2023-11-30 | Seagen Inc. | Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody |
| TW202502352A (zh) | 2023-03-10 | 2025-01-16 | 美商思進公司 | 使用抗ｈｅｒ２抗體－藥物結合物及ｈｅｒ２激酶抑制劑治療癌症之方法 |
| TW202541808A (zh) | 2023-12-20 | 2025-11-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗癌組合治療 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US5413197A (en) | 1994-03-14 | 1995-05-09 | Baer; Larry G. | Parking brake valve |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| CA3060407A1 (en) * | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| TW202042820A (zh) * | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
-
2021
- 2021-09-27 US US18/027,557 patent/US20230372342A1/en active Pending
- 2021-09-27 EP EP21801380.3A patent/EP4217400A1/en active Pending
- 2021-09-27 CN CN202180075987.1A patent/CN116437924A/zh active Pending
- 2021-09-27 IL IL301405A patent/IL301405A/en unknown
- 2021-09-27 AU AU2021349384A patent/AU2021349384A1/en not_active Abandoned
- 2021-09-27 WO PCT/US2021/071606 patent/WO2022067347A1/en not_active Ceased
- 2021-09-27 MX MX2023003406A patent/MX2023003406A/es unknown
- 2021-09-27 CA CA3197165A patent/CA3197165A1/en active Pending
- 2021-09-27 JP JP2023519178A patent/JP2023543261A/ja not_active Withdrawn
- 2021-09-27 KR KR1020237012912A patent/KR20230078705A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230078705A (ko) | 2023-06-02 |
| US20230372342A1 (en) | 2023-11-23 |
| CA3197165A1 (en) | 2022-03-31 |
| CN116437924A (zh) | 2023-07-14 |
| EP4217400A1 (en) | 2023-08-02 |
| WO2022067347A1 (en) | 2022-03-31 |
| IL301405A (en) | 2023-05-01 |
| JP2023543261A (ja) | 2023-10-13 |
| AU2021349384A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003406A (es) | Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| ZA202006318B (en) | Anti-dll3 antibodies and uses thereof | |
| MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
| PE20180798A1 (es) | Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3 | |
| ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
| MX2022003005A (es) | Composiciones y metodos de anticuerpos anti-cd39. | |
| MY150756A (en) | Tumor theraphy with an anti-vegf antibody | |
| PH12022553035A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2023011340A (es) | Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos. | |
| AR126253A2 (es) | Moléculas de unión al antígeno y métodos de uso | |
| PH12022552741A1 (en) | Anti-ox40 antibody and uses thereof | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MY206650A (en) | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab | |
| AU2018345715A8 (en) | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer | |
| AU2021349384A9 (en) | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody | |
| PH12020552159A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| MX2022013920A (es) | Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. | |
| MX2022011160A (es) | Metodos de tratar canceres mutantes de her2 con tucatinib. | |
| MX2025000637A (es) | Moleculas de union al antigeno anti-steap1 y sus usos | |
| WO2018102594A8 (en) | Methods of treating solid tumors with anti-cd200 antibodies |